Diabetes Patients Saw a 54-Fold Surge in Candida Infections Over Five Years

Between 2016 and 2021, the rate of candida infections among diabetic patients at King Fahad Hospital in Medina climbed from 0.18 to 7.60, a 54.5-fold increase that researchers describe as striking even by the standards of a pandemic-disrupted half-decade. The new retrospective published in the Journal of Epidemiology by AM Khateb, WM Mohammedsaeed, HB Shuraym, and colleagues draws on five years of electronic records to show that poor glycemic control is not just a background risk factor for fungal disease; it is, in measurable biochemical terms, a direct driver of it.

Candida parapsilosis overtakes albicans as the dominant species

Among 812 diabetic patients with positive fungal cultures, Candida parapsilosis emerged as the most frequently isolated species, followed by Candida albicans. That ranking matters: C. albicans has historically dominated clinical discussions of candidiasis, so its displacement by C. parapsilosis signals a possible shift in the ecological landscape of hospital-acquired fungal disease. Bloodstream infections were the most common infection type in the cohort, followed by cutaneous and respiratory forms. Sepsis was documented in 8.1% of patients (66 individuals), and peripheral lower limb injuries appeared in 8% (65 patients), underscoring how quickly fungal colonisation can tip into systemic crisis in this population.

Male diabetic patients showed higher incidence of candidiasis than female patients, a pattern that echoes findings in the broader literature on uncontrolled hyperglycemia and Candida susceptibility. The authors also flagged resistance as a growing concern: Candida krusei, Candida dubliniensis, and C. parapsilosis all demonstrated significant antifungal resistance, predominantly in hospitalised patients.

Why over 7 million diabetic Saudis face elevated fungal risk

Saudi Arabia carries one of the heavier diabetes burdens globally, with more than 7 million affected individuals. That number is not incidental context; it sets the scale of the public health problem this study addresses. Fungal infections already affect over a billion people annually worldwide, and they contribute to substantial morbidity and premature mortality in people with diabetes and metabolic disorders, making timely diagnosis and antifungal treatment a priority rather than a nicety.

The biological mechanism linking diabetes to fungal vulnerability is well established but worth stating plainly. High blood glucose impairs immune defences on multiple fronts: neutrophil function deteriorates, the capacity for extracellular trap formation drops, and hyperglycemia drives acidosis that further deregulates the immune response. The Khateb study adds a clinical layer to that mechanistic picture by showing exactly which biomarkers correlate with infection in a real hospital cohort. The surge in case numbers after 2020 also reflects the COVID-19 pandemic's double effect: more immunocompromised patients in hospital settings, and expanded microbiological surveillance that caught infections previously missed.

Fasting glucose, HbA1c, and creatinine as infection predictors

The study's most actionable output is the identification of three biochemical predictors: high fasting glucose, elevated HbA1c, and increased serum creatinine were each significantly associated with higher fungal infection rates. Taken together, these markers describe a patient whose long-term glycemic control has failed and whose kidneys are already under strain, a combination that creates ideal conditions for opportunistic Candida colonisation.

The retrospective design allowed the team to pull demographic data, medical history, fungal isolate profiles, resistance patterns, and biochemical parameters from electronic records spanning 2016 to 2021. Restricting the cohort to patients with confirmed positive fungal cultures kept the analysis grounded in microbiological evidence rather than clinical suspicion alone. Notably, the urogenital tract represents one of the specific sites where candidiasis burden in diabetic patients has been growing, and the broader distribution of infection types in this cohort, from blood to skin to lung, confirms that no single anatomical site dominates the risk profile.

Single-centre scope and absent national surveillance

The study's limitations are honest and important. King Fahad Hospital is a single institution in Medina; infection patterns, dominant species, and resistance profiles may differ substantially across other regions of Saudi Arabia or in outpatient rather than inpatient settings. More structurally, the authors note the absence of a national fungal infection surveillance programme, which means there is no robust baseline against which to compare these numbers at a population level. The true burden of candidiasis in diabetic Saudis almost certainly exceeds what any single-hospital retrospective can capture.

The rapid rise in antifungal resistance, particularly among C. krusei and C. parapsilosis, also raises questions that a retrospective design cannot fully answer. Were resistant strains circulating in the hospital environment, or were they emerging under therapeutic pressure in individual patients? Disentangling those two pathways would require prospective surveillance and genomic typing, neither of which was within scope here.

Targeted antifungal therapy and the case for national surveillance

The study closes with a call for three parallel interventions: improved diagnostic strategies to catch infections earlier, targeted antifungal therapies chosen with resistance profiles in mind, and enhanced national surveillance to track fungal disease across the full diabetic population. On the clinical side, the three-biomarker flag of high fasting glucose plus elevated HbA1c plus rising creatinine offers a practical screening signal that clinicians can act on before culture results arrive.

For patients and the clinicians managing them, the core message is that glycemic control is antifungal prophylaxis by another name. Maintaining optimal blood sugar levels meaningfully reduces the risk of fungal infections by preserving the immune machinery that keeps Candida in check. A 54.5-fold rise in confirmed infections over five years is a striking number, but it is also, in large part, a modifiable one.